secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001437749-24-016616
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia Q1 net loss narrows to $2.3M; CardiAMP HF 86% mortality reduction in subgroup
--------------------------------------------------------------------------------

- Q1 net loss $2.3M vs $3.5M YoY; revenue $55K; operating cash burn $1.5M (improved from $2.6M).
- CardiAMP HF interim: 86% relative risk reduction in mortality for elevated NTproBNP subgroup; final data Q4 2024.
- Confirmatory Phase III HF II trial activated Q1; 250-patient, >90% powered, enrollment goal 2 years.
- CardiALLO low dose cohort completed with no adverse events; partnership with StemCardia for Phase I/II.
- Morph-DNA steerable sheath FDA submission on track for Q2 2024; expected approval Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774924016616/0001437749-24-016616-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774924016616/bcda20240513_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-016616

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer